FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321883156> ?p ?o ?g. }

• W2321883156 endingPage "ii88" @default.
• W2321883156 startingPage "ii88" @default.
• W2321883156 abstract "Introduction: The treatment with antiEGFR therapy (Cetuximab or Panitumumab) is a standard treatment in KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC) in monotherapy or in combination with chemotherapy. Elderly patients (pts) are underrepresented in clinical trials. The aim of this study is evaluate toxicity profile and outcomes in elderly patients with KRASwt mCRC and treated with antiEFGR therapy alone or in combination with chemotherapy. Methods: It has carried out a retrospective study of 23 pts >70 years with KRASwt mCRC who were treated at our institution between February 2008-August 2013 with antiEGFR therapy. Results: The median age of pts was 75 years (70-85). 73% were men, and 27% were women. All pts had ECOG 0-1 and KRASwt mCRC. 91% of pts received Cetuximab weekly (30%) or biweekly (70%) and 9% received Panitumumab at standard dosage in first (30.4% of pts), second (34.8% of pts) o third line (34.8% of pts) of treatment. 30% of pts received monoclonal antibody (mAb) in monotherapy and 70% (16 pts) in combination with chemotherapy: 13% of pts received FOLFOX in combination, 18% received FOLFIRI and 63% of pts received Irinotecan. 31% of pts had a grade 3-4 toxicity related chemotherapy: 1 pt (6% of pts) experienced grade 4 neutropenia, 1 pt experienced grade 4 cardiovascular toxicity, 2 pts (12% of pts) experienced grade 3 diarrhea and 1 pt experienced grade 4 alopecia. No toxic deaths. 65% of pts had cutaneous toxicity related mAb: 73% grade 1-2 toxicity and 27% grade 3-4 toxicity. 35% of pts had diarrhea related mAb and only 2 pts experienced grade 3 diarrhea. 33% of pts (n = 3) experienced hypersensitivity reactions to Cetuximab. 39% of pts had other grade 1-2 toxicities related mAb: asthenia, pruritus and conjunctivitis. 43.5% of pts required dose reduction of the mAb due to toxicity. 3 pts stopped treatment with mAb due toxicity. Response Rate (RR) was assessable in 87% of pts: 35% had a partial response (PR), 10% had stable disease (SD) and 55% of pts had progression disease. Median Progression Free Survival (PFS) was 6.8 months (1.7-15.5) and median Overall Survival (OS) was 10.52 months (1.7-37.6). Conclusion: In our experience treatment with antiEGFR therapy in elderly pts with KRASwt mCRC is feasible, with a manageable toxicity, and effective with a clinical benefit (PR + SD) of 45%, a PFS of 6.8 months and an OS of 10.5 months in previously treated pts mostly (70% of pts)." @default.
• W2321883156 created "2016-06-24" @default.
• W2321883156 creator A5015808214 @default.
• W2321883156 creator A5023654075 @default.
• W2321883156 creator A5034079740 @default.
• W2321883156 creator A5043258913 @default.
• W2321883156 creator A5046092162 @default.
• W2321883156 creator A5047133376 @default.
• W2321883156 creator A5056886824 @default.
• W2321883156 creator A5058529760 @default.
• W2321883156 creator A5071527273 @default.
• W2321883156 creator A5089771462 @default.
• W2321883156 date "2014-06-01" @default.
• W2321883156 modified "2023-09-26" @default.
• W2321883156 title "Toxicity Profile and Outcomes of Antiefgr Treatment in Elderly Patients with KRAS Wild-Type Metastatic Colorectal Cancer. Experience of Virgen DE Las Nieves University Hospital" @default.
• W2321883156 doi "https://doi.org/10.1093/annonc/mdu165.234" @default.
• W2321883156 hasPublicationYear "2014" @default.
• W2321883156 type Work @default.
• W2321883156 sameAs 2321883156 @default.
• W2321883156 citedByCount "0" @default.
• W2321883156 crossrefType "journal-article" @default.
• W2321883156 hasAuthorship W2321883156A5015808214 @default.
• W2321883156 hasAuthorship W2321883156A5023654075 @default.
• W2321883156 hasAuthorship W2321883156A5034079740 @default.
• W2321883156 hasAuthorship W2321883156A5043258913 @default.
• W2321883156 hasAuthorship W2321883156A5046092162 @default.
• W2321883156 hasAuthorship W2321883156A5047133376 @default.
• W2321883156 hasAuthorship W2321883156A5056886824 @default.
• W2321883156 hasAuthorship W2321883156A5058529760 @default.
• W2321883156 hasAuthorship W2321883156A5071527273 @default.
• W2321883156 hasAuthorship W2321883156A5089771462 @default.
• W2321883156 hasBestOaLocation W23218831561 @default.
• W2321883156 hasConcept C121608353 @default.
• W2321883156 hasConcept C126322002 @default.
• W2321883156 hasConcept C141071460 @default.
• W2321883156 hasConcept C143998085 @default.
• W2321883156 hasConcept C2776694085 @default.
• W2321883156 hasConcept C2776705615 @default.
• W2321883156 hasConcept C2777063308 @default.
• W2321883156 hasConcept C2778260052 @default.
• W2321883156 hasConcept C2778332735 @default.
• W2321883156 hasConcept C2778496288 @default.
• W2321883156 hasConcept C2779998722 @default.
• W2321883156 hasConcept C2780259306 @default.
• W2321883156 hasConcept C2780962732 @default.
• W2321883156 hasConcept C2781187634 @default.
• W2321883156 hasConcept C29730261 @default.
• W2321883156 hasConcept C526805850 @default.
• W2321883156 hasConcept C71924100 @default.
• W2321883156 hasConcept C90924648 @default.
• W2321883156 hasConceptScore W2321883156C121608353 @default.
• W2321883156 hasConceptScore W2321883156C126322002 @default.
• W2321883156 hasConceptScore W2321883156C141071460 @default.
• W2321883156 hasConceptScore W2321883156C143998085 @default.
• W2321883156 hasConceptScore W2321883156C2776694085 @default.
• W2321883156 hasConceptScore W2321883156C2776705615 @default.
• W2321883156 hasConceptScore W2321883156C2777063308 @default.
• W2321883156 hasConceptScore W2321883156C2778260052 @default.
• W2321883156 hasConceptScore W2321883156C2778332735 @default.
• W2321883156 hasConceptScore W2321883156C2778496288 @default.
• W2321883156 hasConceptScore W2321883156C2779998722 @default.
• W2321883156 hasConceptScore W2321883156C2780259306 @default.
• W2321883156 hasConceptScore W2321883156C2780962732 @default.
• W2321883156 hasConceptScore W2321883156C2781187634 @default.
• W2321883156 hasConceptScore W2321883156C29730261 @default.
• W2321883156 hasConceptScore W2321883156C526805850 @default.
• W2321883156 hasConceptScore W2321883156C71924100 @default.
• W2321883156 hasConceptScore W2321883156C90924648 @default.
• W2321883156 hasLocation W23218831561 @default.
• W2321883156 hasOpenAccess W2321883156 @default.
• W2321883156 hasPrimaryLocation W23218831561 @default.
• W2321883156 hasRelatedWork W132389072 @default.
• W2321883156 hasRelatedWork W1792988773 @default.
• W2321883156 hasRelatedWork W2071471252 @default.
• W2321883156 hasRelatedWork W2147138752 @default.
• W2321883156 hasRelatedWork W2405565070 @default.
• W2321883156 hasRelatedWork W2617055067 @default.
• W2321883156 hasRelatedWork W2744658167 @default.
• W2321883156 hasRelatedWork W2892376819 @default.
• W2321883156 hasRelatedWork W2999500669 @default.
• W2321883156 hasRelatedWork W4220811422 @default.
• W2321883156 hasVolume "25" @default.
• W2321883156 isParatext "false" @default.
• W2321883156 isRetracted "false" @default.
• W2321883156 magId "2321883156" @default.
• W2321883156 workType "article" @default.